In recent years, with the use of vascular endothelial growth factor A (VEGFA) inhibitors in oncology, the number of patients with kidney disease has increased, mainly manifesting as thrombotic microangiopathy, minimal change nephropathy, and collapsing focal segmental glomerulosclerosis [21, 22]. This evidence concerns the gene VEGFA and kidney disorder.